Hazard | 95.0% CI for Exp(B) | ||||
---|---|---|---|---|---|
ratio | Lower | Upper | p-value | ||
Origin of diagnosis | |||||
IPC | Reference | 1.00 | |||
OPC | 0.37 | 0.20 | 0.67 | < 0.001 | |
Primary care | 0.34 | 0.18 | 0.66 | < 0.001 | |
Emergency department | 0.56 | 0.25 | 1.26 | 0.16 | |
Sex and age | |||||
Women | 1.08 | 0.75 | 1.56 | 0.67 | |
Age | 1.05 | 1.03 | 1.08 | < 0.001 | |
Systolic blood pressure | |||||
< 100 mmHg | Reference | 1.00 | |||
100–130 mmHg | 0.38 | 0.19 | 0.77 | 0.02 | |
> 130 mmHg | 0.26 | 0.13 | 0.52 | < 0.001 | |
Glucose regulation | |||||
P-Glucose > 8,5 mmol/ml | Reference | 1.00 | |||
P-Glucose ≤ 8,5 mmol/ml | 0.91 | 0.62 | 1.31 | 0.60 | |
HbA1c < 52 mmol/mol | Reference | 1.00 | |||
HbA1c 52–70 mmol/mol | 1.49 | 1.07 | 2.56 | 0.02 | |
HbA1c > 70 mmol/mol | 1.46 | 1.18 | 3.82 | 0.01 | |
Kidney function | |||||
eGFR > 60 ml/min | Reference | 1.00 | |||
eGFR 30–59 ml/min | 1.49 | 0.86 | 2.56 | 0.36 | |
eGFR < 30 ml/min | 1.49 | 0.86 | 2.59 | 0.15 | |
LDL-Cholesterol | |||||
LDL < 2,5 mmol/ml | Reference | 1.00 | |||
LDL ≥ 2.5 mmol/ml | 1.46 | 1.01 | 2.11 | 0.04 | |
Pharmacotherapy | |||||
Insulin | 0.80 | 0.52 | 1.22 | 0.30 | |
Metformin | 0.41 | 0.28 | 0.62 | < 0.001 | |
DPP4 | 0.85 | 0.55 | 1.32 | 0.47 | |
GLP1 | 0.96 | 0.54 | 1.73 | 0.90 | |
SGLT2 | 0.20 | 0.06 | 0.64 | 0.01 | |
Aldosterone antagonist | 0.80 | 0.52 | 1.24 | 0.32 | |
Betablocker | 0.97 | 0.66 | 1.44 | 0.89 | |
Calcium antagonist | 0.70 | 0.48 | 1.01 | 0.06 | |
RAASi | 0.74 | 0.51 | 1.07 | 0.11 | |
Statin | 0.39 | 0.27 | 0.57 | < 0.001 | |
Follow-up visit | |||||
Hospital outpatient care > 30 days | Reference | 1.00 | |||
Hospital outpatient care ≤ 30 days | 0.79 | 0.38 | 1.64 | 0.53 | |
Primary care > 30 days | Reference | 1.00 | |||
Primary care ≤ 30 days | 0.53 | 0.37 | 0.77 | < 0.001 |